John P. Bilbrey - Nov 30, 2021 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Director
Signature
/s/ Catherine Powell, as Attorney-in-Fact for John P. Bilbrey
Stock symbol
ELAN
Transactions as of
Nov 30, 2021
Transactions value $
$8,833
Form type
4
Date filed
12/2/2021, 04:15 PM
Previous filing
Nov 5, 2021
Next filing
Dec 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Award $0 +7.31K +52.56% $0.00 21.2K Nov 30, 2021 Direct F1
holding ELAN Common Stock 24.2K Nov 30, 2021 Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Deferred Stock Units Award $8.83K +307 +3.89% $28.74 8.21K Nov 30, 2021 Common Stock 307 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
F2 Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.
F3 The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.
F4 The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.74 on November 30, 2021.